© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
During the 2018 Genitourinary Cancers Symposium, Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, shared results of a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with bladder cancer.